The estimated Net Worth of Michael P Duffy is at least $15 Million dollars as of 16 April 2021. Mr. Duffy owns over 7,500 units of Lantheus Inc stock worth over $11,160,670 and over the last 9 years he sold LNTH stock worth over $2,536,683. In addition, he makes $1,296,700 as Senior Vice President and Law and Public Policy and General Counsel at Lantheus Inc.
Michael has made over 23 trades of the Lantheus Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of LNTH stock worth $163,125 on 16 April 2021.
The largest trade he's ever made was exercising 27,313 units of Lantheus Inc stock on 3 April 2018 worth over $153,499. On average, Michael trades about 5,882 units every 37 days since 2015. As of 16 April 2021 he still owns at least 109,472 units of Lantheus Inc stock.
You can see the complete history of Mr. Duffy stock trades at the bottom of the page.
Michael P. Duffy serves as Senior Vice President, Law and Public Policy and General Counsel of the Company since 2018, as our Senior Vice President, Strategy and Business Development from October 2015 to 2018 and as our General Counsel since January 2008. From 2002 to 2008, he served as Senior Vice President, General Counsel and Secretary of Point Therapeutics, Inc., a Boston-based biopharmaceutical company. Between 1999 and 2001, Mr. Duffy served as Senior Vice President, General Counsel and Secretary of Digital Broadband Communications, Inc., a competitive local exchange carrier. From 1996 to 1999, Mr. Duffy served as Senior Vice President, General Counsel and Secretary of ETC w/tci, a sub-portfolio of TCI Ventures, Inc./Liberty Media Corporation. Mr. Duffy began his legal career with the law firm Ropes & Gray and holds law degrees from the University of Pennsylvania and Oxford University and a Bachelor of Arts degree in History of Science from Harvard College. From 2013 to 2015, Mr. Duffy also served as the Chairman of the Board of Directors of CORAR, the Council on Radionuclides and Radiopharmaceuticals, Inc., a trade association for the radiopharmaceutical industry, and currently serves as a director of that organization.
As the Senior Vice President and Law and Public Policy and General Counsel of Lantheus Inc, the total compensation of Michael Duffy at Lantheus Inc is $1,296,700. There are 3 executives at Lantheus Inc getting paid more, with Mary Heino having the highest compensation of $4,320,910.
Michael Duffy is 59, he's been the Senior Vice President and Law and Public Policy and General Counsel of Lantheus Inc since 2019. There are 8 older and 18 younger executives at Lantheus Inc. The oldest executive at Lantheus Holdings Inc is James Thrall, 76, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862.
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av..., and Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Lantheus Inc executives and other stock owners filed with the SEC include: